Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?
about
Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistanceChanges in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDSHIV replication enhances production of free fatty acids, low density lipoproteins and many key proteins involved in lipid metabolism: a proteomics studyEffects of PPARγ and RBP4 gene variants on metabolic syndrome in HIV-infected patients with anti-retroviral therapyA longitudinal evaluation of the impact of a polylactic acid injection therapy on health related quality of life amongst HIV patients treated with anti-retroviral agents under real conditions of useSelected metabolic and morphologic complications associated with highly active antiretroviral therapy.Epidemiology and management of antiretroviral-associated cardiovascular disease.Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.The pathophysiology of HIV-/HAART-related metabolic syndrome leading to cardiovascular disorders: the emerging role of adipokines.Treatment of HIV-associated facial lipoatrophy: impact on infection progression assessed by viral load and CD4 count.Impact of Highly Active Antiretroviral Therapy on paediatric Human Immunodeficiency Virus-associated left ventricular dysfunction within the Johannesburg teaching hospital complex.In vitro comparative evaluation of monolayered multipolymeric films embedded with didanosine-loaded solid lipid nanoparticles: a potential buccal drug delivery system for ARV therapy.The Role of Nuclear Medicine in the Staging and Management of Human Immune Deficiency Virus Infection and Associated Diseases.Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophyEndocrine abnormalities in HIV-infected women are associated with peak viral load - the Children and Women: AntiRetrovirals and Markers of Aging (CARMA) Cohort.Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia.
P2860
Q24564647-5EA05425-EE31-4589-84A8-E299AE37F12AQ24792952-798E311B-DE40-4697-B8D4-5394CA518BD6Q33361587-471F5CAE-F882-4558-8662-3FA745A5A04EQ34474050-F5641B05-AF4C-40A3-8AC0-6A616D316D6BQ34593181-398E4975-D91F-49BA-9393-2230319391D5Q34631672-C8985C11-D4F1-4A6D-8479-5CFDD9C7705FQ35338096-2AA00156-8C9F-48C0-ABE7-DD671C45FEF5Q35567828-9A996C28-DABD-4495-A90D-57AE3385C2B4Q35607320-1789527E-5903-44E8-B5C2-18416879C8C2Q37141745-FF5663AF-AA9B-4018-AD88-42140326DA19Q37983204-1C20AF44-D7F0-48B0-8BF2-A59AF227F374Q39243464-39BA0515-5961-46DD-9BC1-52515D285478Q39339439-9CFF0186-1E6C-4643-9951-2BFAF8D60F44Q39739985-B4A7991D-4C1B-40FE-8621-E0E3155C655FQ41037315-926B3F6E-8DC8-4642-B0DA-4A7617DACD91Q46665887-F740F146-1F9C-43ED-B76A-C99D33A7D61B
P2860
Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Lipodystrophy syndrome in HIV ...... it and how can it be managed?
@ast
Lipodystrophy syndrome in HIV ...... it and how can it be managed?
@en
type
label
Lipodystrophy syndrome in HIV ...... it and how can it be managed?
@ast
Lipodystrophy syndrome in HIV ...... it and how can it be managed?
@en
prefLabel
Lipodystrophy syndrome in HIV ...... it and how can it be managed?
@ast
Lipodystrophy syndrome in HIV ...... it and how can it be managed?
@en
P2093
P1433
P1476
Lipodystrophy syndrome in HIV ...... it and how can it be managed?
@en
P2093
P2860
P356
10.2165/00002018-200023010-00004
P577
2000-07-01T00:00:00Z
P6179
1045734305